lcs
Joined: 05 Jul 2006
Posts: 65
|
| Posted: Sat Nov 10, 2007 2:27 am Post subject: Newest and Longest acting Antibiotic- Draxxin |
|
|
Pfizer Animal Health has received European approval for its injectable antibiotic Draxxin (tulathromycin) to be used to prevent swine respiratory disease (SRD). The new claim, which is the first of its kind in Europe, means that veterinarians can prevent SRD using a single dose of Draxxin, avoiding many of the problems associated with traditional oral anti infectives. Anti-infectives are often administered in feed or in water, particularly where large groups of animals have to be treated at the same time. However, this method of treatment frequently fails to deliver a predictable dose, Pfizer says, resulting in less effective treatment and an increased risk of creating resistant bacteria. Sick pigs are less likely to eat and drink than healthy ones, so the animals that need treatment the most tend to receive the lowest dose. There may also be palatability issues with oral anti-infectives – some pigs will eat and drink less simply because they do not like the smell or taste of the medication. This problem is compounded by the fact that it is hard to distribute medication evenly in dry, ground feeds. In certain distribution systems, pigs in different pens tend to receive different doses of antiinfective. Even if pigs do eat or drink enough to receive an adequate dose, many antiinfectives have poor bioavailability in the gut, and absorption varies from animal to animal. In addition to unpredictable dosing, oral medication has other drawbacks, Pfizer says. For instance, medication may be spilled into the
general farm environment and remain in hoppers and troughs which may contribute to the development of bacterial resistance. Much more important in this regard is the fact that many zoonotic bacteria reside in the gut, and therefore receive greater exposure to oral antiinfectives
compared with injectables. As well as allowing more predictable dosing, Draxxin can provide a complete course of treatment with a single injection, Pfizer says. After injection, the drug is rapidly distributed to infected tissues, where it remains at levels sufficient to kill key
respiratory pathogens for an extended period: up to 15 days for Mycoplasma hyopneumoniae, up to nine days for Actinobacillus pleuropneumoniae, and up to five days for Pasteurella multocida. Pfizer product manager Dimitri Popov said: “Draxxin is the only swine treatment that can provide up to 15 days of anti-infective activity from just one injection. It has already proved its worth in the treatment of swine respiratory disease in individual animals and, three years from launch, has become the highest selling SRD injectable brand in Europe.
“However, this extension to the Draxxin license now means that veterinarians and farmers can benefit from its unique profile in the
prevention of infection in groups of at-risk animals.
Any queries, please contact
Sunzen Corporation
11, Jln Anggerik Mokara 31/47
40460 Shah Alam, Selangor
Phone; 03-51218998 |
|
